戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 elong predominantly to the IgG class and are complement fixing.
2 activity using flow cytometry assays (FACS), complement-fixing ability, and CDC activity of a panel o
3 nce of systemic delayed hypersensitivity and complement-fixing Abs in this deviant response probably
4 ypersensitivity responses and a reduction in complement-fixing Abs.
5                                 By contrast, complement-fixing alloantibody levels were reduced.
6 oliferative and cytotoxic responses and both complement fixing and immunoglobulin (Ig)G alloantibody
7 kit that measures C1q binding to distinguish complement fixing and nonfixing antibodies, studies show
8 sial infection is postulated to require both complement-fixing and opsonizing antibodies in addition
9 eloped more serum anti-AChR Ab, and had more complement-fixing anti-AChR IgG2a and 2b and less IgG1 t
10 is a second protective mechanism provided by complement-fixing anti-B5 IgG.
11 nd demyelinating variants can be mediated by complement-fixing anti-GM1 ganglioside autoantibodies th
12 were reduced after intravaginal injection of complement-fixing anti-Thy-1.2 and GK 1.5 anti-CD4 antib
13 ing, suggesting the presence of low affinity complement-fixing antibacterial Abs in certain preparati
14 on has been hyperacute rejection mediated by complement fixing antibodies directed against galactose
15   Samples were evaluated for the presence of complement-fixing antibodies (CFAs) against DENV using a
16 C5b-9, C4d, activated C1, and C5a) and major complement-fixing antibodies (Luminex).
17                                              Complement-fixing antibodies and immunoglobulin M and G
18                                              Complement-fixing antibodies are important mediators of
19                        In this murine model, complement-fixing antibodies can deposit into MCMV-infec
20  delayed-type hypersensitivity responses and complement-fixing antibodies on subsequent challenge wit
21                                     However, complement-fixing antibodies remain uncharacterized for
22                                 In contrast, complement-fixing antibodies to merozoites did not decli
23                                              Complement-fixing antibodies to STm develop by 2 years o
24                        The seroprevalence of complement-fixing antibodies was highest against the PvM
25 ata suggest that Pfs230 is a major target of complement-fixing antibodies which may be important for
26                      The prevalence of IgG3, complement-fixing antibodies, and merozoite phagocytosis
27 s in anamnestic production of nonprotective, complement-fixing antibodies, immune complex deposition
28 nd H-DNA recipients developed high titers of complement-fixing antibodies.
29 P < .01) and those with maximum coccidioidal complement fixing antibody titers >/=1:128 (median, 174
30 treated with atRal and then incubated with a complement-fixing antibody followed by stimulation with
31                                              Complement-fixing antibody levels were similar between a
32 s mechanism may place individuals exposed to complement-fixing bacteria at risk for autoimmunity.
33       We propose that C3d mAbs combined with complement-fixing CD20 mAbs can overcome antigen-loss es
34 1.4%) of 58 patients whose anti-coccidioidal complement-fixing (CF) antibodies were detectable and in
35 hown to react with patient anti-Coccidioides complement-fixing (CF) antibody and is a valuable aid in
36               Detection of anti-Coccidioides complement-fixing (CF) antibody is a valuable diagnostic
37 s of CP activation, such as capillary C4d or complement-fixing donor-specific antibodies (DSA).
38 cells led to robust cytotoxicity mediated by complement-fixing DSAs and phagocytic cells.
39                                Patients with complement-fixing DSAs identified by a positive C3d bind
40  with CDC, the current standard in detecting complement-fixing HLA antibodies.
41                                              Complement-fixing HLA class II antibodies were found les
42 ilar, but unexpectedly, the concentration of complement fixing IgG(1) antibodies was lower in a group
43 nd substantial intra-articular deposition of complement-fixing IgG Abs.
44 gamma-/- mice does not suffice to reduce all complement-fixing IgG subclasses, perhaps because as in
45 end-plate damage initiated by the binding of complement-fixing IgG to end-plate AChRs.
46 ure-activated DCs, induce B cells to produce complement-fixing IgG1 and IgG3 Abs.
47 edominance of vascular deposition of the non-complement-fixing IgG2c isotype and a concomitant decrea
48                                  Infusion of complement-fixing IgG3 mAbs resulted in either hyperacut
49 h idiopathic membranous nephropathy have non-complement-fixing IgG4 autoantibodies to the phospholipa
50 neutralize VACV unless the antibodies are of complement-fixing isotypes and complement is present.
51 , nonneutralizing, non-fusion-inhibiting but complement-fixing MAb, B1, provided no significant prote
52 mechanism of xenograft rejection mediated by complement-fixing natural antibodies recognizing alpha(1
53 bstantially diminish renal injury induced by complement-fixing nephrotoxic Ab.
54 d unchanged, implying normal N-glycation and complement-fixing potential, and antibody binding affini